Education
About Us
Working with TipRanks
Follow Us
StageZero Life Sciences Ltd (TSE:SZLS.H)
:SZLS.H
SZLS.H Stock Chart & Stats
C$0.04
--
Market closed
C$0.04
--
Day’s Range― - ―
52-Week RangeC$0.04 - C$0.04
Previous CloseN/A
VolumeN/A
Average Volume (3M)0.00
Market Cap
C$4.94M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.28
Next Earnings
May 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding123,553,050
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
SZLS.H FAQ
What was StageZero Life Sciences Ltd’s price range in the past 12 months?
StageZero Life Sciences Ltd lowest stock price was C$0.04 and its highest was C$0.04 in the past 12 months.
What is StageZero Life Sciences Ltd’s market cap?
StageZero Life Sciences Ltd’s market cap is C$4.94M.
When is StageZero Life Sciences Ltd’s upcoming earnings report date?
StageZero Life Sciences Ltd’s upcoming earnings report date is May 19, 2026 which is in 75 days.
How were StageZero Life Sciences Ltd’s earnings last quarter?
Currently, no data Available
Is StageZero Life Sciences Ltd overvalued?
According to Wall Street analysts StageZero Life Sciences Ltd’s price is currently Overvalued.
Does StageZero Life Sciences Ltd pay dividends?
StageZero Life Sciences Ltd does not currently pay dividends.
What is StageZero Life Sciences Ltd’s EPS estimate?
StageZero Life Sciences Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does StageZero Life Sciences Ltd have?
StageZero Life Sciences Ltd has 123,553,050 shares outstanding.
What happened to StageZero Life Sciences Ltd’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of StageZero Life Sciences Ltd?
Currently, no hedge funds are holding shares in TSE:SZLS.H
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
StageZero Life Sciences Ltd
StageZero Life Sciences Ltd., a vertically integrated healthcare company, develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications in the United States and Canada. Its proprietary platform technology is Sentinel Principle, which identifies novel biomarkers from whole blood. The company's lead product is Aristotle, a multi-cancer panel test for simultaneously screening for various cancers from a single sample of blood with high sensitivity and specificity for each cancer. It also offers ColonSentry, a blood test to determine an individual's current risk for having colorectal cancer; COVID polymerase chain reaction testing and blood test analysis; Prostate Health Index, a screening test for prostate cancer; and BreastSentry, a test to determine a woman's risk for developing breast cancer. The company was founded in 1998 and is headquartered in Richmond Hill, Canada.
Technical Analysis
BioMark Diagnostics
―
Ayurcann Holdings Corp.
―
Telo Genomics Corp
―
Kane Biotech
―
Quest Pharmatech
―